Evolus - A Slightly Risky Buy Ahead Of Q2 Earnings

Group 1 - The article discusses the importance of staying updated on stocks in the biotech, pharma, and healthcare sectors, highlighting the potential for investment opportunities driven by key trends and catalysts [1] - Evolus (NASDAQ: EOLS) has been previously covered with a "Buy" recommendation issued in March 2024, which has been reiterated in a more recent note [1] - The investing group Haggerston BioHealth provides insights for both novice and experienced biotech investors, including product sales forecasts, integrated financial statements, and market analysis [1] Group 2 - The author, Edmund Ingham, has over 5 years of experience in covering biotech, healthcare, and pharma, having prepared detailed reports on more than 1,000 companies [1]